Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis.

Antimicrobial agents and chemotherapy - 1 Dec 2007

Barrow Esther W, Dreier Jürg, Reinelt Stefan, Bourne Philip C, Barrow William W

Abstract excerpt

Bacillus anthracis is innately resistant to trimethoprim (TMP), a synthetic antifolate that selectively inhibits several bacterial dihydrofolate reductases (DHFRs) but not human DHFR. Previously, we were able to confirm that TMP resistance in B. anthracis (MIC > 2,048 microg/ml) is due to the lack of selectivity of TMP for the B. anthracis DHFR (E. W. Barrow, P. C. Bourne, and W. W. Barrow, Antimicrob. Agents...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacillus anthracis
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Folic Acid Antagonists

Share to Microbial Sensitivity Tests

Share to Molecular Structure

Share to Structure-Activity Relationship

Share to Tetrahydrofolate Dehydrogenase

Share to Trimethoprim

Source

Open in PubMed Open full text

Identifiers

PMID: 17875993
DOI: 10.1128/AAC.00628-07
PMCID: PMC2167980

Genes

DHFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis.PMID 17875993Read ↗

Targeted mutations of Bacillus anthracis dihydrofolate reductase condense complex structure−activity relationships.Semantic proximity Read ↗

Rational Exploration of 2,4-Diaminopyrimidines as DHFR Inhibitors Active against Mycobacterium abscessus and Mycobacterium avium, Two Emerging Human PathogensSemantic proximity Read ↗

Toward Broad Spectrum Dihydrofolate Reductase Inhibitors Targeting Trimethoprim Resistant Enzymes Identified in Clinical Isolates of Methicillin Resistant Staphylococcus aureusSemantic proximity Read ↗

In Vitro Efficacy of Next Generation Dihydrotriazines and Biguanides Against Babesiosis and Malaria ParasitesSemantic proximity Read ↗

Inhibition of Antibiotic-Resistant Staphylococcus aureus by the Broad-Spectrum Dihydrofolate Reductase Inhibitor RAB1Semantic proximity Read ↗

Dihydrofolate reductase as a therapeutic targetSemantic proximity Read ↗

Efficacies of lipophilic inhibitors of dihydrofolate reductase against parasitic protozoa.Semantic proximity Read ↗

Comparison of the protection of cells from antifolates by transduced human dihydrofolate reductase mutants.Semantic proximity Read ↗

Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance.Semantic proximity Read ↗

A novel Plasmodium falciparum expression system for assessing antifolate resistance caused by mutant P. vivax dihydrofolate reductase-thymidylate synthase.Semantic proximity Read ↗

Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.Semantic proximity Read ↗

Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.